多发性骨髓瘤及前驱疾病中微小残留病监测与CAR-T细胞治疗进展
本文综述了单克隆丙种球蛋白病从MGUS、SMM至多发性骨髓瘤的疾病谱,指出质谱检测M蛋白、二代流式与测序检测MRD、PET-CT及循环肿瘤细胞检测等技术使亚临床病变与疗效评估更早更准,MRD阴性为强预后标志;BCMA导向CAR-T、双特异性抗体等免疫治疗带来深度缓解,但MRD方法标准化、监管终点验证、CAR-T毒性管理及可及性仍是主要挑战。
要点
- 质谱、二代流式/测序、PET-CT和循环肿瘤细胞检测可更早识别亚临床病变与治疗反应。
- MRD阴性与更长的无进展生存和总生存强相关,是强预后与预测标志。
- BCMA导向CAR-T与双特异性抗体等T细胞重定向治疗获得前所未有的缓解深度。
核心结论
- 高灵敏度检测使骨髓瘤管理从经验观察转向精准指导,MRD阴性是强预后与预测标志。
- T细胞重定向免疫治疗尤其是BCMA导向CAR-T与双特异性抗体获得前所未有的缓解深度。
- MRD方法标准化、MRD作为监管终点的验证、CAR-T毒性管理及经济与地理可及性仍是主要挑战。
研究设计与样本
- 本文为综述,围绕单克隆丙种球蛋白病从MGUS、SMM到多发性骨髓瘤的疾病谱展开。
- 综述涵盖分子诊断、MRD检测技术、克隆演化与微环境机制及T细胞重定向免疫治疗进展。
主要发现
- 质谱用于M蛋白检测,二代流式与测序用于MRD检测,PET-CT与循环肿瘤细胞检测也被纳入高灵敏度技术。
- MRD阴性与延长的无进展生存和总生存强相关。
- 克隆演化、表观遗传重塑及缺氧、细胞因子网络、基质黏附等微环境影响耐药与复发机制。
- BCMA导向CAR-T、双特异性抗体及双抗原或现货型平台等T细胞重定向免疫治疗取得前所未有的缓解深度。
关键数值与推荐
- MRD阴性被描述为强预后与预测标志,与延长的无进展生存和总生存强相关。
- 高灵敏度技术包括质谱检测M蛋白、二代流式与测序检测MRD、PET-CT成像及循环肿瘤细胞检测。
临床怎么用
- 可采用质谱、二代流式/测序、PET-CT和循环肿瘤细胞检测更早识别亚临床病变与治疗反应。
- 可将MRD阴性作为预后与疗效评估的重要参考指标。
- BCMA导向CAR-T与双特异性抗体可用于追求更深缓解,但需管理CAR-T相关毒性并关注可及性。
局限性
- MRD方法学尚需标准化。
- MRD作为监管终点尚待验证。
- CAR-T相关毒性管理仍具挑战。
- 经济、物流与地理障碍限制先进疗法的公平可及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal gammopathies encompass a continuous spectrum of clonal plasma-cell disorders ranging from indolent precursor states, such as MGUS and SMM, to overt multiple myeloma (MM), each distinguished by its biological complexity, clinical course, and therapeutic implications. Recent advances in molecular diagnostics and immune-based therapies have transformed disease management from empirical observation to precision-guided care. Highly sensitive techniques, such as mass spectrometry for M-protein detection, next-generation flow cytometry and sequencing for minimal residual disease (MRD), PET-CT imaging, and circulating tumor cell assays, have enabled earlier and more accurate detection of subclinical disease and treatment response. MRD negativity has emerged as a powerful prognostic and predictive marker, correlating strongly with prolonged progression-free and overall survival. Parallel insights into clonal evolution, epigenetic remodeling, and microenvironmental influences, including hypoxia, cytokine networks, and stromal adhesion, have deepened understanding of resistance and relapse mechanisms. Therapeutically, the development of T-cell-redirecting immunotherapies, especially BCMA-directed CAR-T cells, bispecific antibodies, and emerging dual-antigen or "off-the-shelf" platforms, has achieved unprecedented response depth. Nonetheless, major challenges remain, including standardization of MRD methodologies, the validation of MRD as a regulatory endpoint, management of CAR-T-related toxicities, and overcoming economic, logistical, and geographic barriers that limit equitable access to advanced therapies. Addressing these challenges will be essential to translating molecular precision and cellular innovation into durable remission and, ultimately, a functional cure for multiple myeloma.
引用
- El-Sehrawy AAMA, Oriquat G, Saidov S, et al. Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders. Clin Chim Acta. 2026. PMID: 42140377. doi:10.1016/j.cca.2026.121066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。